Bridgepoint completed the acquisition of PharmaZell Group, an independent manufacturer of niche active pharmaceutical ingredients, from Deutsche Private Equity and Maxburg Capital Partners. Financial terms were not disclosed. "PharmaZell represents an exciting opportunity to invest in a robust platform with an experienced management team and a high-quality customer base in the growing and non-cyclical pharma market. With a strong track record of growth, the company also offers the prospect of further new products and with Bridgepoint will have the resources and reach to further develop selective acquisition opportunities," Carsten Kratz, Bridgepoint Senior Partner.